

**COMPARATIVE EFFECTIVENESS RESEARCH LEGISLATION:
DIFFERENCES IN THE HOUSE AND SENATE VERSIONS OF THE BILL**

ISSUE	HOUSE (H.R. 2502)	SENATE (S.1213)
Name of Institute	Health Care Comparative Effectiveness Research Institute	Patient-Centered Outcomes Research Institute
Expert Advisory Panels	No mention of special cases for rare diseases.	Must consult expert advisory panel when researching a rare disease.
Quality of Life	No mention of quality of life preferences.	Research must take quality of life preferences into account.
Treatment Modalities	No mention of different treatment modalities.	Research must take differences of treatment modality into account (i.e. phase of treatment, skill of operator of treatment)
Study on Conducting Research In-House	No requirement for in-house research report.	The Institute must conduct a study and submit a report on the feasibility of conducting research in-house.
Support for Patient/Consumer Representatives	No mention of patient/consumer representative support.	In Institute must provide support/resources (i.e. education, activities) to help patient/consumer representative on the expert advisory panels.
Methodology Committee	No numerical requirements.	May not exceed 17 members.
Methodological Standards	No mention of necessary/suggested input for developing standards.	The process for developing standards should include input from relevant experts, stakeholder, and decision makers.
Coordination of Research	No mention of coordinating research.	The Institute must coordinate research with public and private agencies to ensure efficient use of resources and that no research is unnecessarily duplicated.
Annual Report	No annual report requirement.	The Institute must submit an annual report to Congress and the President which will be available to the public.
Board of Governors	No specifications for Board.	Secretary of HHS, Director of AHRQ, 18 appointed members (representing patients, physicians, CMS, state and federal health programs, private payers, manufacturers, NPOs, quality measurement organizations, independent health services researchers).
Funding Assessment	No funding assessment specifications.	The Comptroller General of the U.S. will assess the adequacy and use of funding for the Institute.
Conflicts of Interest	No mention of conflicts of interest.	In appointing members to the advisory groups, the Institute must include a description of any conflicts of interest.

